The signing took place at The Westin Cairo Golf Resort and Spa, Katameya Dunes, with senior leadership from both sides in attendance. Dr. Fahad Khater, Chairman of Alameda Healthcare Group, and Neeraj Mishra, Group CEO, represented Alameda. Nine specialist surgeons from RoboMasters were also present, reflecting the breadth of clinical expertise the group brings to the table.

The partnership will use Edge Medical’s robotic surgery platform, combining the technology with RoboMasters’ surgical expertise across multiple specialties. The goal is to improve surgical precision, extend minimally invasive capabilities, and give Egyptian patients broader access to procedures that, until recently, were largely available only through medical travel abroad.

How will it work?

RoboMasters is not a single clinic or hospital. It is a structured group of surgeons who specialise in robotic techniques across urology, gynaecology, and general surgery. Under this agreement, they will work within Alameda’s existing infrastructure to build out comprehensive robotic surgery programs. The collaboration also covers clinical training, which means the long-term aim is to grow local surgical expertise, not simply import it.

Alameda currently operates four JCI-accredited hospitals across Greater Cairo, including as-Salam International Hospital in Maadi, ASSIH New Cairo, Dar Al Fouad Nasr City, and Dar Al Fouad 6th of October City. The group also runs outpatient and rehabilitation facilities. That network gives the partnership real reach. Robotic surgery will not be confined to a single site.

Why does it matter?

Minimally invasive surgery reduces hospital stays, lowers infection risk, and typically shortens recovery times. But robotic-assisted procedures require significant capital investment and trained surgical teams, which is why adoption across the region has been uneven. This deal addresses both barriers at once, pairing the hardware investment with a ready-made team of experienced robotic surgeons.

Speaking at the signing, Mishra said the partnership reflects Alameda’s wider commitment to clinical innovation and to raising surgical standards in Egypt and the broader region. That framing matters. Egypt has the population and the healthcare demand to support serious investment in advanced surgical technology, and deals like this one signal that private operators are prepared to move beyond incremental upgrades.

The context

Robotic surgery adoption across the Arab world has accelerated in recent years, driven by Vision 2030 in Saudi Arabia and the UAE’s ongoing push to become a regional medical hub. Egypt, with a population of over 100 million, has its own healthcare reform agenda, and the private sector is increasingly central to delivering on it. Alameda’s JCI accreditation across its hospital network already places it at the top end of the Egyptian market. Adding a structured robotic surgery program strengthens that position and puts the group in direct competition with the more advanced surgical offerings available in the Gulf. For patients, that competition is exactly what drives quality up.

The post Alameda Healthcare and RoboMasters sign EGP 70 million robotic surgery deal in Egypt appeared first on DH Arab.

What’s the news?

Egyptian President Abdel Fattah Al-Sisi met with Orange Group CEO Christel Heydemann in late September, alongside Communications Minister Raafat Hendy and senior Orange executives for the Middle East, Africa, and Egypt. The meeting covered telecommunications cooperation, digital skills, and technology investment, but the sharpest ask from the Egyptian side was direct: join the second phase of the national digital health project.

Al-Sisi called on Orange to contribute to that second phase specifically in digital infrastructure, cloud computing, cybersecurity, and systems integration. He also urged the group to scale up training programmes that prepare young Egyptians for jobs in AI, data analytics, and cloud computing, including through internationally recognised professional certifications delivered via global technology partners.

Orange’s announced commitments include the 200,000-person training initiative, the €25 million startup fund targeting AI and advanced technologies, and laboratory installations at a number of Egyptian universities. Heydemann said Orange’s Egypt work could act as a reference model for other markets across the region, particularly in Africa.

Why does it matter?

Digital health is one of the most investment-heavy and strategically sensitive sectors in any national tech agenda. Egypt’s first phase of its national digital health project laid groundwork for electronic medical records, telehealth infrastructure, and health data systems. Bringing a major telecoms and technology group like Orange into the second phase would add serious cloud and connectivity muscle to that build-out.

The workforce angle is just as significant. Egypt has one of the largest youth populations in the Arab world, and the government has made digital skills central to its economic strategy. A commitment from Orange to deliver AI and cybersecurity training at scale, with recognised certifications attached, addresses a real gap. Skilled talent is consistently cited by regional tech investors as a constraint on growth.

Still, important details are missing. The presidency’s statement did not specify a timetable for implementation, how the €25 million startup fund will be distributed, or which universities will receive the new laboratories. Those gaps matter for anyone trying to assess what this partnership will actually deliver.

The context

Across the GCC and broader Arab world, governments are racing to build out digital health infrastructure as part of wider national transformation programmes. Saudi Vision 2030 and the UAE’s various health and AI strategies have pushed regional ambitions higher and raised expectations for what technology partnerships should look like. Egypt is working on a different budget and scale, but the direction is the same.

Orange has a long-standing presence in Egypt and the wider Middle East and Africa region. Its involvement in digital education and smart platforms gives it credibility beyond pure connectivity. But the move to position Egypt as a model for African markets is notable. It suggests Orange sees the country not just as a local market, but as a proof-of-concept for a broader regional and continental strategy.

For health technology companies, infrastructure providers, and investors tracking where the next wave of digital health contracts will land, Egypt’s second-phase ambitions are worth watching closely.

The post Egypt presses Orange Group to join digital health expansion as tech investment deepens appeared first on DH Arab.

The partnership is straightforward in concept but significant in practice. Transaction amounts are sent automatically from cashier screens to the Fawry Business POS terminal. Once a payment is completed, the transaction status updates in the DMS system in real time. No one types the same number twice. No one checks a printout against a spreadsheet at the end of the day.

For hospitals and clinics running high volumes of daily transactions, that kind of automation matters. Payment bottlenecks at the front desk affect patient flow, staff productivity, and revenue reconciliation. Solving them through system-level integration, rather than workarounds or manual processes, reflects a broader shift in how healthcare facilities in the region are approaching operational management.

How will it work?

The integration creates a direct channel between DMS’s medical management platform and the Fawry Business POS infrastructure. Key features of the integration include:

• Automatic transfer of transaction amounts from cashier screens to the POS terminal
• Real-time status updates within the DMS system once payment is confirmed
• Elimination of manual data re-entry between the POS and the back-office system
• Faster settlement processes with improved data accuracy
• Reduced risk of human error across payment and reconciliation workflows

Bassem Lotfy, Head of Business Development at Fawry, described the logic behind the move: “Our collaboration with DMS represents a practical step toward connecting payments with business management systems, contributing to the automation of processes, reducing manual intervention, and improving the accuracy and speed of transactions across the healthcare sector.”

Roaa Mamdouh, Strategic Alliances Director at DMS, added that the goal is to allow “transaction data and status to move automatically between the system and the POS without the need for manual intervention,” pointing to both hospitals and businesses as the intended beneficiaries.

Why does it matter?

Healthcare administration in the Arab world is under growing pressure to modernise. Patient volumes are rising, regulatory expectations around billing and data accuracy are tightening, and staff shortages make manual processes increasingly unsustainable. An integration that removes a layer of human intervention from the payment cycle is not a small thing. It directly affects how quickly patients move through a facility and how confidently finance teams can close their books.

But the implications stretch beyond hospitals. DMS also works in the financial and industrial sectors, meaning the Fawry Business integration could extend its reach across multiple verticals. For Fawry, which has spent years building Egypt’s largest electronic payments network, this kind of embedded integration is a logical next step. Payments that sit inside workflows are stickier, more useful, and harder to replace than standalone terminals.

The context

Egypt’s digital payments sector has expanded rapidly over the past several years, driven by regulatory reform, a growing base of banked and digitally active consumers, and deliberate investment in fintech infrastructure. Fawry is central to that story. It processes millions of transactions daily across a network that spans consumer payments, bill settlement, and now business-to-system integrations.

Across the wider region, the direction of travel is the same. GCC countries, particularly Saudi Arabia and the UAE, have placed healthcare digitisation at the centre of their national development agendas. Saudi Vision 2030 includes explicit targets for connected health systems. The UAE has invested heavily in unified health platforms and integrated billing environments. Egypt’s private healthcare sector is watching those models closely, and partnerships like this one signal that the infrastructure to support similar integration is now being built locally.

So this is one partnership, in one market. But it points toward something larger: a regional shift in which payments are no longer processed beside healthcare systems, but inside them.

The post Fawry and DMS link payment terminals directly to hospital management systems in Egypt appeared first on DH Arab.

This is still at proposal stage, but the ambition is clear. Egypt is signaling that it wants to move beyond fragmented, paper-heavy healthcare delivery and build something more coordinated at scale. The involvement of Inspur, one of China’s largest cloud computing and AI firms, and MTS, a technology services provider with experience in health digitization, suggests the ministry is looking at proven international models rather than starting from scratch.

How will it work?

Based on what the ministry has outlined, the platform is designed to do several things at once. The core functions would include:

• Connecting hospitals, clinics, and other health facilities through a shared digital network
• Creating integrated electronic health records that follow patients across facilities
• Embedding AI tools to support diagnostics, treatment recommendations, and administrative efficiency
• Offering telemedicine services to extend access, particularly in underserved or remote areas

Minister Abdel Ghaffar reviewed China’s own experience in health digitization before these meetings, which suggests the ministry is treating Beijing’s infrastructure build-out as a reference point. China has spent the past decade connecting over a billion patients to centralized digital records, and Inspur has been a key technical partner in that effort.

Why does it matter?

Egypt has a population of over 100 million people and a health system under significant pressure. Doctor-to-patient ratios in rural governorates are stretched, referral pathways are inconsistent, and duplicate testing is common because records rarely follow patients between facilities. A unified platform would address all of these issues directly, at least in theory.

The AI and telemedicine components also matter for equity. If deployed correctly, they could extend specialist access to patients in Upper Egypt or the Delta who currently have to travel to Cairo for consultations. That’s a real and measurable benefit, not just a headline.

But digital health infrastructure is only as good as its implementation. Interoperability, data privacy, and clinician adoption are where similar projects have stalled elsewhere in the region.

The context

Egypt is not operating in isolation here. Across the GCC and broader Arab world, health digitization has become a policy priority. Saudi Arabia’s Vision 2030 has made digital health a core pillar of its healthcare reform agenda. The UAE has its unified health platform, Malaffi, connecting Abu Dhabi’s hospitals and clinics. Qatar and Bahrain have their own electronic health record initiatives well advanced.

Egypt, with its far larger population and more complex public health infrastructure, faces a bigger challenge. But it also has an opportunity to build something with genuine regional significance. If this platform moves from proposal to execution, it will be one of the largest health digitization projects in the Arab world by population coverage. The conversations with MTS and Inspur are a starting point. What happens next will depend on funding, political will, and how seriously the ministry treats the harder questions around data governance and system integration.

The post Egypt eyes national digital health platform to unify patient records and AI services appeared first on DH Arab.

The two companies announced a strategic agreement that gives inDrive drivers access to Vezeeta’s “Shamel” programme, an annual healthcare subscription that offers discounts of up to 80% on medical services. The deal is not a generic corporate wellness gesture. It is structured around inDrive’s existing driver loyalty tiers, which means the benefits are calibrated to reward engagement with the platform.

How will it work?

Drivers at the top of inDrive’s loyalty structure, classified as “Legendary” drivers, will receive complimentary Shamel subscriptions. All other inDrive drivers, and their families, are eligible for a 25% discount on Shamel subscriptions. The Shamel programme itself has no age restrictions, no exclusions for chronic conditions, and no caps on how many times a subscriber can access services throughout the year. There is also no requirement for prior authorisation, which removes one of the most common friction points in healthcare access.

Through the Vezeeta app, subscribers can:

• Book doctor consultations
• Order pharmacy products
• Schedule phone-based follow-up appointments
• Request home visits from doctors
• Book laboratory tests and radiology services

Alaa El-Din Shalaby, General Manager of inDrive Egypt, described the move as a natural extension of the company’s commitment to its driver community. “Our drivers are the driving force behind everything we do,” he said, “and supporting their health and well-being is among our top priorities.”

Why does it matter?

Gig and platform workers across the Arab world are a growing labour segment, but they rarely enjoy the occupational health benefits that come with formal employment. No employer-sponsored insurance. No sick leave. And in many cases, deferred medical care because the cost and time commitment feels unmanageable.

This partnership does not solve that structural problem. But it does make a practical difference. A driver who can book a specialist consultation at 80% off, without navigating insurance paperwork, is more likely to actually seek care. And that matters at scale. inDrive operates in more than 1,200 cities across 48 countries, and its app has been downloaded over 400 million times, making it the second most downloaded smart mobility application globally.

Dr. Ola Ali El-Din, Chief Operating Officer at Vezeeta, said the deal fits the company’s broader strategy of building partnerships with organisations that share a genuine interest in expanding healthcare access. “inDrive was one of the key companies where we saw a strong commitment to providing better healthcare solutions for its drivers,” she said.

The context

Vezeeta is one of the region’s most established health-tech platforms, operating across the Middle East and Africa with a network of more than 30,000 healthcare providers. The Shamel subscription model reflects a wider shift in how digital health platforms are approaching affordability. Rather than relying solely on insurance integration, subscription-based access is emerging as a parallel route to making routine care financially manageable.

In Egypt specifically, where out-of-pocket healthcare spending remains significant, that approach carries real weight. The government’s own health coverage reforms under Egypt Vision 2030 have made progress, but private-sector initiatives that extend affordable care to informal and semi-formal workers are filling gaps that public programmes have not yet reached. Partnerships like this one, anchored in existing digital platforms with large user bases, may prove to be one of the more efficient ways to move the needle on population health access in the near term.

The post inDrive and Vezeeta join forces to bring subsidised healthcare to Egypt’s ride-hailing drivers appeared first on DH Arab.

The ministry confirmed the discussions are focused on establishing an investment fund dedicated to biotech and medical technologies. The goal, broadly, is to pull in private capital, support locally grown innovation, and lift the quality of healthcare services across the country.

How would it work?

The details are still taking shape, but the framework being discussed would channel venture capital specifically into biotechnology and medical technology companies. This is distinct from general healthcare investment. Biotech and medtech require longer development cycles, higher risk tolerance, and specialised expertise that most traditional funds are not built for. A dedicated vehicle would theoretically attract investors who understand that profile and are willing to back Egyptian startups and research initiatives over a longer horizon.

Gold Rock Venture’s involvement suggests the fund could follow a model seen elsewhere in emerging markets, where private fund managers partner with government-backed health ministries to co-invest in strategic sectors. Whether the Egyptian state would take a direct stake or simply act as an enabler is not yet clear.

Why does it matter?

Egypt has a large population, a growing burden of non-communicable disease, and a pharmaceutical manufacturing base that already exports across Africa and the Arab world. What it has lacked is a structured way to move early-stage health innovation from research institutions into commercial products. A dedicated fund addresses that gap directly.

It also fits a broader pattern across the region. Saudi Arabia’s Vision 2030 has made local biotech production a national priority since COVID-19 exposed supply chain vulnerabilities. The UAE has built out health innovation clusters in Abu Dhabi and Dubai. Egypt, with its scientific talent pool and manufacturing capacity, has the ingredients. The missing piece has been capital with the right structure and patience.

The context

Egypt’s health sector has been undergoing serious reform over the past several years, anchored by the rollout of its Universal Health Insurance system. That programme is expanding coverage but also creating new demand for locally produced medicines, diagnostics, and devices. A biotech and medtech fund would support the supply side of that equation.

The meeting in New Alamein is also symbolic in its location. The new administrative and governmental hub represents Egypt’s wider push to modernise its institutions and project a different image to international investors. Hosting this kind of conversation there, rather than in Cairo, is a small but deliberate signal. Still, signals need to be followed by structure, legal frameworks, and committed capital. The real test will be whether this fund moves from ministerial meetings to a formal launch.

The post Egypt eyes biotech investment fund as healthcare ambitions grow appeared first on DH Arab.

The track is now live inside what Al Mokhtabar calls its Mega Lab, a central processing facility that supports a network of more than 460 branches and roughly five million patient visits a year. The lab already holds College of American Pathologists accreditation, a standard it has maintained for 15 consecutive years and the only Egyptian lab to do so.

The move is part of a broader push by Al Mokhtabar’s parent company, Integrated Diagnostics Holdings (IDH), to automate more of its testing workflow and reduce the time between a sample arriving and a result reaching a doctor.

How does it work?

The FLEXLAB-X is a connected conveyor and processing system that moves samples through the lab without human handling at most stages. Here is what the installed system can do at Al Mokhtabar’s Mega Lab:

• Process up to 30,000 samples and 87,000 individual tests per day
• Return results in an average of 32.4 minutes, well below the lab’s own internal target of 120 minutes
• Store more than 25,000 samples in automated refrigerated units after testing
• Retrieve and reuse a stored sample in under 30 seconds if a doctor orders an additional test, with no need to take a new blood draw from the patient

The system also uses artificial intelligence to monitor the mechanical condition of its own devices, predict faults before they cause downtime, and run statistical checks on results to flag anything that looks out of range before it reaches a clinician.

The range of tests the system handles is wide. It covers clinical chemistry, immunoassays, oncology markers, cardiac biomarkers, thyroid function, liver disease, multiple sclerosis indicators, and infectious disease testing.

Why does it matter?

Speed is the obvious win here. Cutting average turnaround from a 120-minute target to just over 32 minutes is a meaningful change for doctors making time-sensitive decisions, particularly in cardiology and oncology where early results can change a treatment path quickly.

The automated sample retrieval feature also has a real patient benefit. If a doctor orders a follow-up test after seeing an initial result, the lab can pull the original sample from cold storage and run the new test without calling the patient back in for another blood draw. That reduces inconvenience and speeds up the diagnostic process.

For Al Mokhtabar, the capacity numbers matter too. At 87,000 tests per day, the system gives the lab room to grow without adding proportional headcount or floor space. The company says the track can scale as demand increases.

The context

Lab automation has been accelerating across the Middle East over the past few years as health systems in the region try to manage growing patient volumes with flat or limited staffing budgets. Installing high-throughput automation at a central hub and feeding it through a branch network is one of the more proven models for doing that at scale.

Al Mokhtabar’s approach, centralizing complex testing at one highly automated facility while keeping a large branch network for sample collection and routine results, mirrors what several large European and Asian lab groups have built over the past decade. The FLEXLAB-X installation is a step toward that model becoming standard in North Africa.

Siemens Healthineers is one of the largest medical technology companies in the world, with around 74,000 employees and revenue of approximately 23.4 billion euros in its fiscal year ending September 2025. Winning the first FLEXLAB-X placement in the Middle East and Africa at a lab with Al Mokhtabar’s scale and accreditation status is a useful reference point for the company as it competes for further contracts in the region. More details on the system are available at siemens-healthineers.com.

The post Egypt’s largest diagnostic lab installs the first Siemens FLEXLAB-X automation track in the Middle East and Africa appeared first on DH Arab.

Reme-D, founded in 2022 by Salma Tammam, develops and manufactures tests for diseases including tuberculosis, HIV, hepatitis, and HPV at its facility in Cairo. What sets the company apart is its focus on tests that work without refrigeration, which matters enormously in remote or under-resourced settings where keeping reagents cold is often impossible.

The round was led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures, and other investors. The funding follows a $500,000 investment from the Global Innovation Fund last April.

How does it work?

Since launching, Reme-D has developed and sold 30 diagnostic products and supplied more than 550,000 tests across Egypt, Kenya, and Sudan. Its customers include public and private laboratories, hospitals, and research institutions. The company has also filed a US patent application for its core technology.

One recent project shows the practical ambition behind the business. Reme-D equipped a solar-powered mobile laboratory commissioned by the WHO Egypt country office, used by Egypt’s Ministry of Health to monitor vector-borne diseases in remote areas where permanent lab infrastructure doesn’t exist.

With the new funding, the company plans to:

• Move to a 1,500 square metre facility in Cairo and upgrade equipment, increasing production capacity by ten times
• Expand into more African markets and build out regulatory capabilities
• Add new diagnostic products covering genetic diseases and cancer
• Make more products temperature-resilient for easier transport and storage in low-infrastructure settings

The company has grown from five to 50 employees since 2023.

Why does it matter?

Access to molecular diagnostics in sub-Saharan Africa and the broader Global South has long been limited by two problems: cost and supply chain fragility. Most advanced diagnostic tests are manufactured in the US, Europe, or East Asia, then shipped to Africa, often requiring cold storage throughout the journey. When that chain breaks, the tests become useless.

Reme-D is building tests locally, keeping costs lower and cutting out some of the logistics complexity. Its temperature-resilient design also means tests can reach clinics and hospitals that have no reliable refrigeration.

Mohamed Hussain, Principal at Anara Impact Capital, said the firm was impressed by the team’s ability to “combine deep scientific expertise with a clear understanding of the realities of delivering diagnostics in underserved markets.”

Tammam put it plainly: “Success means that patients in Africa and the Global South are no longer blocked from life-altering disease diagnosis by cost or availability of an advanced molecular test in their area.”

The context

Africa’s diagnostics market has attracted growing investor attention in recent years, partly driven by lessons from the COVID-19 pandemic, which exposed how dependent the continent was on imported testing products. Several African governments and development finance institutions have since pushed for local manufacturing of health tools, from vaccines to diagnostics.

Reme-D fits squarely into that push. The company’s products have already appeared in international scientific publications, which adds credibility beyond commercial sales and suggests the technology meets rigorous standards. The US patent application signals that the company is also thinking about protecting its intellectual property as it scales.

For Africa-focused healthtech, local manufacturing combined with a scientifically validated product is a more durable position than distribution-only models, which remain vulnerable to global supply shocks. Whether Reme-D can hold that position as it grows into new markets will be the real test.

The post Egyptian diagnostic startup Reme-D raises $1.45 million to scale affordable testing across Africa appeared first on DH Arab.

The meeting centered on expanding remote healthcare access across the country, with a focus on connecting more patients to medical professionals without requiring them to travel to clinics or hospitals. For a country of over 100 million people, many of whom live far from major urban centers, that kind of access can make a real difference.

Egypt has been working to modernize its health infrastructure for several years now, and telemedicine has become a key part of that strategy. This latest meeting suggests the government is looking to move faster, and is bringing in private sector partners to help do it.

How does it work?

Telemedicine lets patients consult with doctors remotely, typically through video calls, messaging platforms, or dedicated apps. In Egypt’s case, the government appears to be working with both technology providers and medical institutions to build out the infrastructure needed to make this work at scale.

TeleMed’s involvement points to a platform-based approach, where patients can access care through a digital interface rather than visiting a physical facility. Novartis, as a pharmaceutical company, likely brings expertise around medication management and patient monitoring, both of which are critical components of any remote care model.

Why does it matter?

Telemedicine isn’t new, but making it work at a national level in a country like Egypt is genuinely hard. The challenges are real:

• Large rural populations with limited access to specialists
• Pressure on urban hospitals and clinics that are already stretched thin
• A need for affordable care options as costs rise
• Varying levels of digital literacy among patients

If Egypt can get this right, it could significantly improve health outcomes for millions of people who currently have limited access to quality care. It also positions the country as a leader in digital health across the broader region.

The context

Egypt launched its Universal Health Insurance system in recent years as part of a wider effort to improve healthcare access. Digital tools, including telemedicine, are seen as essential to making that system work efficiently at scale.

Globally, telemedicine saw a massive surge during the COVID-19 pandemic and has remained a priority for governments and health systems ever since. Countries across Africa and the Middle East are increasingly investing in digital health infrastructure, and Egypt’s latest moves fit squarely into that trend. The involvement of a multinational like Novartis also signals growing private sector interest in the Egyptian health market.

The post Egypt pushes to expand telemedicine and digitize its healthcare system appeared first on DH Arab.

The discussions covered three main areas: medical training, digital transformation, and modernising the country’s training infrastructure. Egypt’s Ministry of Health and Population confirmed the meeting in an official statement, describing it as part of a broader push to bring private sector expertise into the public health system.

No specific deals or agreements were announced, but the meeting signals that both sides are actively exploring what a formal partnership could look like.

How will it work?

Details are still thin, but the conversation centred on a few clear priorities:

• Expanding medical training programs, likely using Samsung’s technology and devices
• Pushing digital tools further into Egypt’s healthcare workflows
• Upgrading the physical and technical infrastructure used to train health workers

Samsung Electronics already has an established presence in Egypt, which gives this kind of public-private conversation a practical foundation rather than a speculative one.

Why does it matter?

Egypt has one of the largest populations in Africa and the Middle East, with over 105 million people. Improving healthcare delivery at scale requires more than funding. It requires better systems, better-trained staff, and technology that works reliably in high-demand environments.

Bringing a company like Samsung into that equation matters because the firm has experience rolling out health tech solutions in other markets, from hospital display systems to medical imaging support. If Egypt can structure a real partnership rather than a photo-opportunity meeting, there is genuine potential to speed up the country’s digital health agenda.

The context

Egypt has been working to modernise its health sector for several years, partly through its Universal Health Insurance program, which is one of the most ambitious public health reforms the country has attempted. Digital infrastructure is a known weak point in that rollout.

Across the region, governments are increasingly turning to large technology companies to help close gaps in healthcare capacity. Saudi Arabia, the UAE, and Jordan have all signed similar cooperation agreements with major tech firms in recent years. Egypt’s conversation with Samsung fits that wider pattern, even if it is still at an early stage.

Whether this meeting leads to something concrete will depend on what both sides agree to fund, build, and measure. For now, it is a signal of intent more than a done deal.

The post Egypt’s health ministry explores tech partnership with Samsung Electronics appeared first on DH Arab.